Pharmaceutical manufacturers have long struggled to create an
efficient clinical trial process for faster next-phase approval. The root
cause of most failures is a lack of necessary efficacy data to support
clinical trial claims. Moses Zonana and Danahlyn Tamola at CMT
discuss the ways that will contribute to more efficient follow-up of
clinical trials and therefore for faster clinical trial approval.